Regeneron Pharmaceuticals (REGN) FY2021 results: revenue $16.1 billion, up 89.1% on the year
Regeneron Pharmaceuticals, Inc. (REGN) reported revenue of $16.1 billion for fiscal 2021, the year ended 31 December 2021, up 89.1% on the year before. Net income was $8.1 billion, up 129.9%, and diluted earnings per share $71.97. The figures are the company's own, from the 10-K it filed with the SEC on 7 February 2022.
Revenue
$16.1 billion
+89.1% on the year
FY2014FY2021
Operating margin
55.7%
42.1% a year earlier
FY2014FY2021
Net income
$8.1 billion
+129.9% on the year
FY2014FY2021
Diluted EPS
$71.97
+135.8% on the year
FY2014FY2021
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2021
FY2020
FY2019
On the year
Last 8 years
Operating cash flow
7,081
2,618
2,430
+170.5%
Capital expenditure
552
615
430
-10.2%
Free cash flow
6,529
2,004
2,000
+225.9%
Free cash flow margin
40.6%
23.6%
30.5%
Cash from investing
-5,385
-70.6
-2,028
Cash from financing
-1,006
-1,970
-252
Depreciation and amortisation
286
236
210
+21.3%
Share-based compensation
602
432
464
+39.3%
Buybacks
1,645
5,847
276
-71.9%
Diluted shares, weighted
112m
115m
115m
-2.5%
Balance sheet
$ million
FY2021
FY2020
FY2019
On the year
Last 8 years
Shareholders' equity
18,769
11,025
11,090
+70.2%
Short-term borrowings
n/a
n/a
0.0
Debt
1,980
1,978
0.0
+0.1%
Finance lease liabilities
0.0
717
714
Other liabilities
4,686
3,442
3,002
+36.1%
Total liabilities and equity
25,435
17,163
14,805
+48.2%
Fixed assets
3,482
3,222
2,890
+8.1%
Intangible assets
6.7
n/a
n/a
Investments
9,647
4,529
4,853
+113.0%
Cash and equivalents
2,886
2,194
1,618
+31.5%
Receivables
6,036
4,115
2,100
+46.7%
Inventory
1,951
1,917
1,416
+1.8%
Other assets
1,425
1,188
1,928
+20.0%
Total assets
25,435
17,163
14,805
+48.2%
10-K for the year ended 31 December 2021, filed 7 February 2022: the filing.